

**KHS2 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7972b****Specification**

---

**KHS2 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession  
Other Accession[Q8IVH8](#)  
[NP\\_003609](#)**KHS2 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 8491**Other Names**

Mitogen-activated protein kinase kinase kinase 3, Germinal center kinase-related protein kinase, GLK, MAPK/ERK kinase kinase kinase 3, MEK kinase kinase 3, MEKKK 3, MAP4K3, RAB8IPL1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7972b](/product/products/AP7972b) was selected from the C-term region of human KHS2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**KHS2 Antibody (C-term) Blocking Peptide - Protein Information****Name** MAP4K3 ([HGNC:6865](#))**Synonyms** RAB8IPL1**Function**

Serine/threonine kinase that plays a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway (PubMed:[9275185](http://www.uniprot.org/citations/9275185)). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:[26437443](http://www.uniprot.org/citations/26437443)).

**Tissue Location**

Ubiquitously expressed in all tissues examined, with high levels in heart, brain, placenta, skeletal muscle, kidney and pancreas and lower levels in lung and liver

**KHS2 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**KHS2 Antibody (C-term) Blocking Peptide - Images****KHS2 Antibody (C-term) Blocking Peptide - Background**

KHS2, a member of the Ste20 subfamily of Ser/Thr protein kinases, features the characteristic N-terminal catalytic domain and C-terminal regulatory domain of the Ste20 subfamily. The kinase activity of the encoded protein can be stimulated by UV radiation and tumor necrosis factor- $\alpha$ . The protein specifically activates the c-Jun N-terminal kinase (JNK) signaling pathway. Evidence suggests that it functions upstream of mitogen-activated protein kinase kinase kinase 1 (MEKK1). This gene previously was referred to as RAB8-interacting protein-like 1 (RAB8IPL1), but it has been renamed mitogen-activated protein kinase kinase kinase 3 (MAP4K3).

**KHS2 Antibody (C-term) Blocking Peptide - References**

Diener, K., et al., Proc. Natl. Acad. Sci. U.S.A. 94(18):9687-9692 (1997).